Evidence map›Paper›PMID 31768009›Full record

ArticleBone marrow transplantation2020

The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Giulia Tolomelli, Katia Mancuso, Paola Tacchetti, Francesca Patriarca, Monica Galli, Lucia Pantani, Beatrice Zannetti, Maria Rosa Motta, Simonetta Rizzi, Elisa Dan and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Giulia TolomelliSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Katia MancusoSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Paola TacchettiSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Francesca PatriarcaDepartment of Hematology and Cellular Therapy 'Carlo Melzi', "S. Maria della Misericordia" University Hospital, DAME, University of Udine, Udine, Italy.
Monica GalliHematology and Bone Marrow Transplant Unit, 'Papa Giovanni XXIII' Hospital, Bergamo, Italy.
Lucia PantaniSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Beatrice ZannettiSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Maria Rosa MottaSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Simonetta RizziSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Elisa DanSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Barbara SinigagliaSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Valeria GiudiceApheresis Unit, Transfusion Medicine Center, University Hospital S. Orsola-Malpighi, Bologna, Italy.
Andrea OlmoApheresis Unit, Transfusion Medicine Center, University Hospital S. Orsola-Malpighi, Bologna, Italy.
Mario ArpinatiSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Gabriella ChirumboloSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Renato FaninDepartment of Hematology and Cellular Therapy 'Carlo Melzi', "S. Maria della Misericordia" University Hospital, DAME, University of Udine, Udine, Italy.
Russell E LewisDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Laura ParisHematology and Bone Marrow Transplant Unit, 'Papa Giovanni XXIII' Hospital, Bergamo, Italy.
Francesca BonifaziSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.ORCID http://orcid.org/0000-0003-1544-9911
Michele CavoSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. michele.cavo@unibo.it.
Antonio Curti *Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Roberto M Lemoli *Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy.
University of Bologna · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITOspedale Papa Giovanni XXIII · ITUniversity of Udine · ITOspedale Infermi di Rimini · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plerixafor inhibits CXCR4, thus inducing the mobilization of hematopoietic stem/progenitor cells in lymphoma and multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT). However, the kinetics of plerixafor-induced mobilization of lymphocyte subsets is poorly known. Here, we evaluated the graft content, the engraftment, and the immunological reconstitution of MM patients receiving plerixafor. Thirty-seven patients undergoing one or tandem ASCT were enrolled. After mobilization with cyclophosphamide plus G-CSF, plerixafor was added at hematological recovery regardless of CD34

Indexed as

Hematopoietic Stem Cell TransplantationHeterocyclic CompoundsMultiple MyelomaBenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansTransplantation, AutologousBenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixafor

Identifiers

PMID31768009
OpenAlexW2990788045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.